Best of TTLC 2024 Webinar
Webinar | English | 2024 | 60 Min
Image For Activity Cover
Credit Offered
1 ACCME Credit
1 Certificate of Attendance Credit
Key points of this webinar encompass significant research findings presented at the 2024 Targeted Therapies in Lung Cancer (TTLC) conference held in Santa Monica, CA. The landscape of lung cancer therapy is swiftly advancing with the introduction of numerous novel drugs and treatment approaches in the past year. With emerging evidence, there exist opportunities to enhance patient outcomes, and we aim to facilitate the dissemination of this knowledge to our audience for the integration of these innovative practices.
Live Activity Date: March 29, 2024
Enduring Activity Launch Date: April 12, 2024
Enduring Activity Expiration Date: April 11, 2025
This activity is designed to meet the education needs of health care professionals in medical oncology, thoracic surgery, radiation oncology and pathology.
Upon completion of this activity, the participants should be able to: 
  • Explain optimal treatment recommendations and indications for patients with EGFR mutated NSCLC.
  • Identify optimal perioperative treatments for patients with early-stage NSCLC.
  • Summarize the role for novel therapies in metastatic lung cancer. 
  • Kaushal Parikh, MBBS, Medical Oncologist/Assistant Professor of Oncology, Mayo Clinic, Rochester, MN, USA 
  • Amit Kulkarni, MBBS, Thoracic Medical Oncologist/Assistant Professor, University of Minnesota Medical School, Minneapolis, MN, USA
  • Antoinette Wozniak, MD, FACP, FASCO, Medical Oncologist/Chief Science Officer, The Lung Cancer Research Foundation, Pittsburgh, PA, USA
  • Joshua Reuss, MD, Medical Oncologist/Assistant Professor, Georgetown University Medical Center, Washington, D.C., USA
The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name Commercial Interest Role Level of Participation in the Activity
Clarissa Baldotto AstraZeneca Advisor, Speaker Planner
  Roche Advisor  
  Roche Brazil Speaker  
  Pfizer Advisor  
  Takeda Speaker  
  MSD Brazil Advisor, Speaker  
  Novartis Advisor  
  Janssen Advisor, Speaker  
Amit Kulkarni Genentech Advisory Board Speaker
  Exelixis Advisory Board  
  Regeneron Speaker  
  AstraZeneca Research Funding  
  Fate Therapeutics Stock/Stock Options  
  Exact Sciences Stock/Stock Options  
  Gilead Sciences Stock/Stock Options  
  Mirati Therapeutics Stock/Stock Options  
  Novavax Stock/Stock Options  
  Abbvie Stock/Stock Options  
  Lilly Stock/Stock Options  
Kaushal Parikh AstraZeneca Advisor Moderator
  Jazz Pharmaceuticals Advisor  
Joshua Reuss Sanofi Advisor Speaker
  Personalis Advisor  
  Guardant Advisor  
  AstraZeneca Advisor  
  BMS Advisor  
  Arcus Advisor  
  Abbvie Advisor  
  Daiichi Sankyo Advisor  
  Catalym Advisor  
  Seagen Advisor  
  Gilead Advisor  
  Janssen Advisor  
  Novacure Advisor  
  Regeneron Advisor  
  Genentech Research Funding  
  Verastem Research Funding  
  Nuvalent Research Funding  
  Exelixis Research Funding  
  AstraZeneca Honoraria  
  Merck Honoraria  
Antoinette Wozniak EPIC Speaker Speaker
  AstraZeneca Consultant  

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

The International Association for the Study of Lung Cancer designates the live or enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

International CPD Credit Reciprocity Agreements

The Royal College will recognize the number of participation hours as MOC Program Section 1 accredited group learning credits for group learning activities developed by Accreditation Council for Continuing Medical Education (ACCME)-accredited physician organizations (university, academy, specialty society, hospital department etc.) that are held within and outside of Canada. Agreement dates: November 1, 2019 to December 31, 2025.

European Union
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (

The American Medical Association (AMA) and the Department of Healthcare Professions–Accreditation Section (DHP-AS), Ministry of Public Health–Qatar have renewed their CME agreement under which select activities approved for AMA PRA Category 1 Credit™ are eligible for conversion of the hours of participation to Department of Healthcare Professions Continuing Professional Development (DHP-CPD) credit. This agreement is in place through Dec. 31, 2026.
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:
  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out, if applicable.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.
  4. Complete the activity evaluation to provide feedback for future programming and receive credit.
You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.
If you need assistance with this activity, please email:
Powered By